I'm still eager. Depending on the status of the Pliaglis milestone payment, I'm expecting to see them report approximately $13 million in cash as of 12/31/12. That number along with Pennsaid revenues are what I'm most looking forward to seeing. We won't really start getting any feel for Pliaglis commercial success until August (when 2Q2013 results are released).
I also hope the company will give a more concrete timeline on when they plan to re-submit for Pennsaid 2% approval. But honestly, as long as it's not later than the previously mentioned 3Q2012, I'll be happy enough.